Targeted radionuclide therapy for neuroendocrine tumours.

2003 ◽  
pp. 497-501 ◽  
Author(s):  
V J Lewington
Keyword(s):  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Treatment Success ◽  
Future Research ◽  
Potential Contribution ◽  
Targeted Radionuclide Therapy ◽  
Effective Option ◽  
High Tumour Uptake ◽  
Radiolabelled Peptide

Evidence supporting the potential contribution of targeted radiotherapy to the management of neuroendocrine tumours is now strong. Acting systemically, this is an effective option for patients with inoperable or multi-site disease. Toxicity is generally low, being limited to reversible myelosuppression and theoretical nephrotoxicity. Prerequisites for treatment success include demonstration of high tumour uptake relative to non-target tissues on quantitative diagnostic radionuclide imaging and stable haematological and biochemical function. In addition to (131)I metaiodobenzylguanidine therapy, which is now well established, there is growing interest in radiolabelled peptide therapy using a range of somatostatin receptor analogues such as (90)Y DOTATOC and (90)Y lanreotide. The results of clinical experience are summarised and the direction for future research is discussed.

scholarly journals RADIONUCLIDE IMAGING AND THERAPY OF NEUROENDOCRINE TUMOURS

2015 ◽  
Vol 1 (2) ◽  
Author(s):  
Shaunak Navalkissoor ◽  
Gopinath Gnanasegaran
Keyword(s):  
Radionuclide Imaging ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Clinical Results ◽  
It Use ◽  
Peptide Receptor ◽  
Mibg Therapy

The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise. Although NETs are a heterogeneous group of tumours, they have some similar properties, for example, that they can concentrate neuroamines and tend to have a high degree of somatostatin receptor (SSR) expression. These mechanisms can be exploited and this article discusses the important role of radionculide imaging and radionculide therapy in the management of NETs based on these mechanisms. This article reviews the current literature and discusses the role of radionuclide imaging in NETs both in terms of SSR imaging and neuroamine (metaiodobenzylguanidine [MIBG]) imaging. We discuss state-of- the-art 68Ga-radiopeptide imaging and indications for it use. We also discuss the role of 18F-FDG and other tracers in the management of NETs. The second half of the article focuses on radiotargeted treatment of NETs, discussing I-131 MIBG therapy and focussing on the emergence of peptide receptor radionuclide therapy. We discuss the clinical results, toxicities and patient selection for PRRT. Key words: DOTA octreotide, DOTATATE, Ga-68, Lu-177, metaiodobenzylguanidine, neuroendocrine tumours, peptide receptor radionuclide therapy, Y-90 

scholarly journals [177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy

2001 ◽  
Vol 92 (5) ◽  
pp. 628-633 ◽  
Author(s):  
Marion de Jong ◽  
Wout A.P. Breeman ◽  
Bert F. Bernard ◽  
Willem H. Bakker ◽  
Michael Schaar ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Somatostatin Receptor ◽  
Targeted Radionuclide Therapy

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings

2002 ◽  
Vol 32 (2) ◽  
pp. 133-140 ◽  
Author(s):  
Marion de Jong ◽  
Roelf Valkema ◽  
Francois Jamar ◽  
Larry K. Kvols ◽  
Dik J. Kwekkeboom ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Somatostatin Receptor ◽  
Clinical Findings ◽  
Targeted Radionuclide Therapy

scholarly journals Targeted Radionuclide Therapy for Neuroendocrine Tumours: Principles and Application

2010 ◽  
Vol 91 (1) ◽  
pp. 1-15 ◽  
Author(s):  
Maralyn R. Druce ◽  
Val Lewington ◽  
Ashley B. Grossman
Keyword(s):  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Targeted Radionuclide Therapy

scholarly journals Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to68Ga-DOTATATE/-TOC uptake

2016 ◽  
pp. now060 ◽  
Author(s):  
Katharina Seystahl ◽  
Veit Stoecklein ◽  
Ulrich Schüller ◽  
Elisabeth Rushing ◽  
Guillaume Nicolas ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Somatostatin Receptor ◽  
Targeted Radionuclide Therapy

Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours

2019 ◽  
Vol 12 (2) ◽  
pp. 126-134 ◽  
Author(s):  
Shahad Alsadik ◽  
Siraj Yusuf ◽  
Adil AL-Nahhas
Keyword(s):  
Side Effects ◽  
Effective Treatment ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Peptide Receptor Radionuclide Therapy ◽  
Progression Free Survival ◽  
Treatment Modalities ◽  
Effective Treatment Option ◽  
Peptide Receptor ◽  
Pancreatic Neuroendocrine Tumours

Background: The incidence of pancreatic Neuroendocrine Tumours (pNETs) has increased considerably in the last few decades. The characteristic features of this tumour and the development of new investigative and therapeutic methods had a great impact on its management. Objective: The aim of this review is to investigate the outcome of Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of pancreatic neuroendocrine tumours. Methods: A comprehensive literature search strategy was used based on two databases (SCOPUS, and PubMed). We considered all studies published in English, evaluating the use of PRRT (177Luteciuim- DOTA-conjugated peptides and 90Yetrium- DOTA- conjugated peptides) in the treatment of pancreatic neuroendocrine tumours as a standalone entity or as a subgroup within the wider category of Gastroenteropancreatic Neuroendocrine Tumours (GEP NETs). Results: PRRT was found to be an effective treatment modality as a monotherapy or in combination with other therapies in the treatment of non-operable and metastatic pNETs where other options are limited. Complete response was reported to be between 2-6% while partial response was achieved in up to 60% of cases. Survival analysis was also impressive. Progression Free Survival (PFS) reached a mean of 34 months and Overall Survival (OS) of 53 months. PRRT also proved to improve patients’ Quality of Life (QoL). Acute and sub-acute side effects like nephrotoxicity and haematotoxicity are usually mild and reversible. Conclusion: PRRT is well tolerated and effective treatment option for non-operable and/or metastatic pNETs. Side effects are usually mild and reversible. Larger randomized controlled trails need to be done to compare PRRT with other treatment modalities and to provide more detailed guidelines regarding patient selections, the choice of PRRT, follow up and response assessment to maximum potential benefit.

Sign in / Sign up

Export Citation Format

Share Document